Corporate Board Profile
Tech Score: 20/100
1 mention(s) identify ROHIN MHATRE, PH.D. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| REPLIGEN CORP | 2025-04-04 | Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows. | He holds a Ph.D. in Chemistry and has extensive technical expertise in biopharmaceutical development, including leading teams responsible for cell line, cell culture, purification, and device development, indicating strong technical and scientific skills that likely include programming or software-related expertise. |
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-21 | Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience. He serves as a member of the Compensation Committee. |
| 2022-04-11 | Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. ... Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. ... The Compensation Committee, of which Mr. Barthelemy, Mr. Muir and Dr. Mhatre are currently members, is responsible for: ... Director Compensation Table for the Fiscal Year Ended December 31, 2021 shows total compensation $220,051. |
| 2023-04-11 | Rohin Mhatre, Ph.D. Senior Vice President, Product and Technology Development, Biogen Inc. 58 2020 ✓ - • 70,000 191,322 191,218 452,540 |
| 2024-04-01 | Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings 30 years of relevant experience to the director role. |
| 2025-04-04 | Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows. |
Data sourced from SEC filings. Last updated: 2025-08-30